Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia.

MLA

Moore, Oliver M., et al. “Long-Term Efficacy and Safety of Cardiac Genome Editing for Catecholaminergic Polymorphic Ventricular Tachycardia.” The Journal of Cardiovascular Aging, vol. 4, no. 1, Jan. 2024. EBSCOhost, https://doi.org/10.20517/jca.2023.42.

APA

Moore, O. M., Aguilar-Sanchez, Y., Lahiri, S. K., Hulsurkar, M. M., Alberto Navarro-Garcia, J., Word, T. A., Keefe, J. A., Barazi, D., Munivez, E. M., Moore, C. T., Parthasarathy, V., Davidson, J., Lagor, W. R., Park, S. H., Bao, G., Miyake, C. Y., & Wehrens, X. H. T. (2024). Long-term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia. The Journal of Cardiovascular Aging, 4(1). https://doi.org/10.20517/jca.2023.42

Chicago

Moore, Oliver M, Yuriana Aguilar-Sanchez, Satadru K Lahiri, Mohit M Hulsurkar, J Alberto Navarro-Garcia, Tarah A Word, Joshua A Keefe, et al. 2024. “Long-Term Efficacy and Safety of Cardiac Genome Editing for Catecholaminergic Polymorphic Ventricular Tachycardia.” The Journal of Cardiovascular Aging 4 (1). doi:10.20517/jca.2023.42.